Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01133210 · ClinicalTrials.gov registry record · Phase 1
Effect of Maraviroc on Metabolic Function in Obese Subjects (Phase I)
A Phase 1 study of Hypertriglyceridemia, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
- 1
- Study location
NCT01133210 is a Phase 1 study of Hypertriglyceridemia that has completed, run by Washington University School of Medicine. The registered enrollment target is 27 participants, below the 175-participant average among 25 other Hypertriglyceridemia trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01133210, a Phase 1 study of Hypertriglyceridemia, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the effect of maraviroc therapy in obese insulin resistant subjects on: 1. Plasma triglyceride concentration 2. Plasma HDL-cholesterol and LDL-cholesterol concentrations 3. Plasma markers of cardiometabolic risk and inflammation
Conditions Studied
Interventions
- OTHER placebo
- DRUG Maraviroc
Study Locations (1)
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2011-01 |
| Est. Completion | 2012-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01133210
The ClinicalTrials.gov registry entry for NCT01133210 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 175-participant average among 25 other Hypertriglyceridemia trials with a reported enrollment target (85% lower). The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hypertriglyceridemia appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT01133210 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT01133210 about?
NCT01133210 is a clinical study titled "Effect of Maraviroc on Metabolic Function in Obese Subjects (Phase I)". The purpose of this study is to determine the effect of maraviroc therapy in obese insulin resistant subjects on: 1. Plasma triglyceride concentration 2. Plasma HDL-cholesterol and LDL-cholesterol concentrations 3. Plasma markers of cardiometabolic risk and inflammation
What is the current status of trial NCT01133210?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2011-01. Estimated completion is 2012-11.
What conditions does trial NCT01133210 study?
This clinical trial studies the following conditions: Hypertriglyceridemia.
What interventions are being tested in trial NCT01133210?
The interventions under investigation include: placebo (OTHER), Maraviroc (DRUG).
Who is sponsoring clinical trial NCT01133210?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01133210 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertriglyceridemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of RN0361in Adult Healthy Subjects and Adult Hypertriglyceridemic Subjects
ACTIVE NOT RECRUITING · Phase 1
-
Interaction of Epanova on Warfarin Pharmacokinetic and Anticoagulant Activity and Comparison of the Effects of Epanova and Lovaza on Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) After Low-fat Meals
COMPLETED · Phase 1
-
PK Study Comparing Metformin Eicosapentaenoate to a Combined Dose of Metformin Hydrochloride and Ethyl Ester EPA
COMPLETED · Phase 1
-
The Effect of Multiple Doses of Epanova® on the Multiple-Dose Pharmacokinetics of Simvastatin in Healthy Normal Subjects
COMPLETED · Phase 1
-
Study to Evaluate the 2-Way Interaction Between Multiple Doses of Epanova™ and a Single Dose of Rosuvastatin (Crestor®)
COMPLETED · Phase 1
-
Study of Gemcabene in Adults With FPLD
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.